Efficacy of erythropoietin alone in treatment of neonates with hypoxic-ischemic encephalopathy: A protocol for systematic review and meta-analysis

Guang Yang, MD\textsuperscript{a,*}, Zhimin Xue, MD\textsuperscript{b}, Yuan Zhao, MD\textsuperscript{b}

Abstract

Background: Multiple clinical trials have demonstrated the safety and efficacy of erythropoietin in improving neurodevelopmental outcomes in infants with hypoxic-ischemic encephalopathy (HIE). It is undoubtedly urgent to include only randomized controlled trials (RCTs) for more standardized systematic reviews and meta-analyses. The purpose of this study is to examine whether erythropoietin reduces the risk of death and improve neurodevelopmental disorders in infants with HIE.

Methods: The electronic databases of Cochrane Library, EMBASE, PubMed, and Web of Science were searched from the inception to June 2021 using the following key terms: “erythropoietin,” “hypoxic-ischemic encephalopathy,” and “prospective,” for all relevant RCTs. Only English publications were included. The primary outcome was mortality rate. Secondary outcomes included neurodevelopmental disorders, brain injury, and cognitive impairment. The Cochrane risk of bias tool was independently used to evaluate the risk of bias of included RCTs by 2 reviewers.

Results: We hypothesized that group with erythropoietin would provide better therapeutic benefits compared with control group.

OSF registration number: 10.17605/OSF.IO/FERUS.

Abbreviations: HIE = hypoxic-ischemic encephalopathy, RCTs = randomized controlled trials.

Keywords: erythropoietin, hypoxic-ischemic encephalopathy, meta-analysis, protocol, random, systematic review

1. Introduction

Perinatal hypoxic-ischemic encephalopathy (HIE) is an important cause of neonatal encephalopathy, occurring in 1 to 3 of every 1000 births in the United States and affecting as many as 12,000 infants annually in the United States.\textsuperscript{[1]} About a quarter of HIE survivors show permanent neurological sequelae, such as cerebral palsy, mental retardation, blindness, and deafness. Treatment for the disease remains limited. Hypothermia, which begins within 6 hours of birth, improves prognosis. Still, 46% of babies are at risk of death or disability. New neuroprotective therapies are needed to further reduce the high risk of adverse outcomes after HIE.\textsuperscript{[2,3]}

Erythropoietin has neuroprotective and neuroregenerative effects, which are net effects of anti-excitatory, anti-inflammatory, anti-oxidant, and anti-apoptotic effects on neurons and oligodendrocytes.\textsuperscript{[4]} In addition, erythropoietin promotes neurogenesis, oligodendrogenesis, and angiogenesis, which are essential for normal neurodevelopment and injury repair.\textsuperscript{[5,6]} These beneficial effects of erythropoietin have been well documented in experimental models of neonatal brain injury, and emerging clinical data also show benefits. The safety of high doses of erythropoietin in newborns is also reassuring.\textsuperscript{[7]}

Multiple clinical trials have demonstrated the safety and efficacy of erythropoietin in improving neurodevelopmental outcomes in infants with HIE.\textsuperscript{[8–10]} A recent review involving randomized and non-randomized trials assessed neurodevelopmental disorders in infants with HIE. The authors did not explicitly define neurodevelopmental disorders, nor did they assess the risk and level of evidence for bias.\textsuperscript{[11]} Therefore, it is undoubtedly urgent to include only randomized controlled trials (RCTs) for more standardized systematic reviews and meta-analyses. The purpose of this study is to examine whether erythropoietin reduces the risk of death and improve neurodevelopmental disorders in infants with HIE.

2. Materials and methods

2.1. Selection of studies

The systematic review protocol was registered on Open Science Framework registries. Two independent investigators followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines to conduct this study. The...
electronic databases of Cochrane Library, EMBASE, PubMed, and Web of Science were searched from the inception to June 2021 using the following key terms: “erythropoietin,” “hypoxic-ischemic encephalopathy,” and “prospective,” for all relevant RCTs. Furthermore, the reference lists from published original articles and relevant reviews were assessed to identify more relevant studies. Only English publications were included. Ethical approval was not necessary because the present meta-analysis was performed on the basis of previous published studies.

2.2. Inclusion and exclusion criteria

Included studies would be considered eligible if they met the population, intervention, comparator, outcomes, and study design criteria as follows:

Population: neonates with HIE;
Intervention: group with erythropoietin;
Comparator: group without erythropoietin;
Outcomes: The primary outcome was mortality rate. Secondary outcomes included neurodevelopmental disorders, brain injury, and cognitive impairment.

Study design: RCTs.

Exclusion criteria included observational studies, review articles, studies with a sample size <50, and studies with insufficient outcome data.

2.3. Data extraction

Data were extracted by review of each study for population, mean age, sex, follow-up duration, study design, publishing date, characteristics, and outcomes assessment. The 2 reviewers created a study-specific spreadsheet in Excel for data collection. Data extraction was performed independently, and any conflict was resolved before final analysis. Any disagreements between the 2 reviewers were discussed and, if necessary, the third author was referred to for arbitration. If the data were missing or could not be extracted directly, authors were contacted by email. If necessary, we would abandon the extraction of incomplete data.

2.4. Risk of bias assessment

The Cochrane risk of bias tool was independently used to evaluate the risk of bias of included RCTs by 2 reviewers. The quality of RCTs was assessed by using following 7 items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Kappa values were used to measure the degree of agreement between the 2 reviewers and were rated as follows: fair, 0.40 to 0.59; good, 0.60 to 0.74; and excellent, ≥0.75.

2.5. Data synthesis

The present study was performed by Review Manager Software (RevMan Version 5.3, The Cochrane Collaboration, Copenhagen, Denmark). We used the Mantel-Haenzel method to calculate the pooled odds ratio. Odds ratio with a 95% confidence interval was assessed for dichotomous outcomes. P <0.05 was set as the significance level. The heterogeneity was assessed by using the Q test and I² statistic. When I² ≥40%, it was considered to represent significant heterogeneity. All outcomes were pooled on random-effect model. The Z test was used to assess the overall effect.

3. Discussion

Multiple clinical trials have demonstrated the safety and efficacy of erythropoietin in improving neurodevelopmental outcomes in infants with HIE.[10] A recent review involving randomized and non-randomized trials assessed neurodevelopmental disorders in infants with HIE. The authors did not explicitly define neurodevelopmental disorders, nor did they assess the risk and level of evidence for bias.[11] Therefore, it is undoubtedly urgent to include only RCTs for more standardized systematic reviews and meta-analyses. The purpose of this study is to examine whether erythropoietin reduces the risk of death and improve neurodevelopmental disorders in infants with HIE. We hypothesized that group with erythropoietin would provide better therapeutic benefits compared with control group.

Author contributions

Conceptualization: Yuan Zhao.
Data curation: Guang Yang, Zhimin Xue.
Formal analysis: Guang Yang, Zhimin Xue.
Investigation: Guang Yang, Zhimin Xue.
Methodology: Yuan Zhao.
Project administration: Yuan Zhao.
Resources: Guang Yang, Software: Zhimin Xue.
Supervision: Yuan Zhao.
Validation: Guang Yang, Zhimin Xue.
Visualization: Guang Yang.
Writing – original draft: Guang Yang.
Writing – review & editing: Yuan Zhao.

References

[1] Nonomura M, Harada S, Asada Y, et al. Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: an open-label pilot study to assess the safety and feasibility. BMC Pediatr 2019;19:13.
[2] McPherson RJ, Juul SE. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr 2010;22:139–45.
[3] Lobo N, Yang B, Rizvi M, Ma D. Hypothermia and xenon: novel noble guardians in hypoxic-ischemic encephalopathy? J Neurosci Res 2013;91:473–8.
[4] Lv HY, Wu SJ, Wang QL, et al. Effect of erythropoietin combined with hypothermia on serum tau protein levels and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy. Neural Regen Res 2017;12:1655–63.
[5] Juul SE, Pet GC. Erythropoietin and neonatal neuroprotection. Clin Perinatol 2015;42:469–81.
[6] Malla RR, Asmi R, Teli MA, Shaheen F, Bhat MA. Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol 2017;37:596–601.
[7] Zhou KQ, Davidson JO, Bennett L, Gunn AJ. Combination treatments with therapeutic hypothermia for hypoxic-ischemic neuroprotection. Dev Med Child Neurol 2020;62:1131–7.
[8] Wu YW, Mathur AM, Chang T, et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics 2016;137:e20160191.
[9] Rogers EE, Bonfacio SL, Glass HC, et al. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatr Neurol 2014;51:657–62.
[10] Hagaz AA, El Frargy MS, Abd El-Latif AE. Study of cord blood erythropoietin, leptin and adiponectin levels in neonates with hypoxic ischemic encephalopathy. Endocr Metab Immune Disord Drug Targets 2020;20:213–20.
[11] Garg B, Sharma D, Bansal A. Systematic review seeking erythropoietin role for neuroprotection in neonates with hypoxic ischemic encephalopathy: presently where do we stand. J Matern Fetal Neonatal Med 2017;31:3214–24.